drugset / Trial / NCT00439010
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
Phase 1
Completed
30 enrolled
Molecular NeuroImaging
Institute for Neurodegenerative Disorders · collab
Non-randomizedSingle-groupSingle-blindDiagnostic
Summary
The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
Timeline
- Start
- 2007-02
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 123-I AV39 | Diagnostic / imaging agent | — | — |